Results 271 to 280 of about 75,785 (301)
Some of the next articles are maybe not open access.
Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor
Blood, 2010Abstract Abstract 3262 Relapsed acute lymphoblastic leukemia (ALL) remains a difficult challenge for both pediatric and adult patients. Chimeric antigen receptors (CARs) are genetically engineered molecules expressed in transduced T lymphocytes. CARs express both a target binding motif and TCRzeta signals needed for T cell
Daniel W. Lee +4 more
openaire +1 more source
Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Blood
Approximately 30-60% of relapses after CD19 CAR T therapy for B-acute lymphoblastic leukemia (B-ALL) occur with loss of CD19 expression (CD19-), often with persistent CAR T. Strategies under investigation to reduce this risk include co-targeting of CD22.
Xiaopei Lily Zeng +3 more
openaire +1 more source
Approximately 30-60% of relapses after CD19 CAR T therapy for B-acute lymphoblastic leukemia (B-ALL) occur with loss of CD19 expression (CD19-), often with persistent CAR T. Strategies under investigation to reduce this risk include co-targeting of CD22.
Xiaopei Lily Zeng +3 more
openaire +1 more source
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Archives of Iranian medicine, 2020Current advancements in the field of chimeric antigen receptor (CAR) therapy, particularly U.S. FDA approval of Kymriah and Yescarta, heralds a new era of cancer treatment. This rapid progress in technology has urged more countries and institutions to keep pace with the fast-growing and developing technology of producing CAR T cell-based therapies in ...
Jafar, Kiani +6 more
openaire +1 more source
CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy
BloodAbstract Chimeric antigen receptor T cells (CAR T) targeting CD19 can cure approximately a third of patients with aggressive B cell malignancies, but relapse due to CD19 antigen loss and serious infections resulting from B cell aplasia remain major causes of death following CD19 CAR T.
Brian Betts +12 more
openaire +1 more source
CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
Journal of Clinical Oncology, 2019PURPOSE Anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatment of chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL). There are now two US Food and Drug Administration (FDA)–approved products available for treating these patients, and a third product is expected to be approved
openaire +2 more sources